Treating myeloma: The future is already here!

Ola Landgren, Neha Korde

Research output: Contribution to journalComment/debatepeer-review

6 Scopus citations


In this issue of Blood, Jakubowiak and colleagues report outstanding results from a phase 1/2 study using carfilzomib - a next-generation proteasome inhibitor that selectively and irreversibly binds to the proteasome, targeting chymotrypsin-like activity - in combination with lenalidomide and low-dose dexamethasone in newly diagnosed multiple myeloma patients. The study shows excellent response rates, deep and durable responses, continued responses during treatment, and limited severe toxicities.

Original languageEnglish (US)
Pages (from-to)1754-1756
Number of pages3
Issue number9
StatePublished - Aug 30 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Treating myeloma: The future is already here!'. Together they form a unique fingerprint.

Cite this